Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics

This study has been completed.
Sponsor:
Collaborator:
UMC Utrecht
Information provided by:
The Netherlands Asthma Foundation
ClinicalTrials.gov Identifier:
NCT00200954
First received: September 12, 2005
Last updated: August 13, 2008
Last verified: May 2007

September 12, 2005
August 13, 2008
January 2004
December 2007   (final data collection date for primary outcome measure)
Incidence and severity of atopic disease at the age of 2 years. Incidence and prevalence of eczema [ Time Frame: Follow-up at 3 months, 12 months, and 24 months ] [ Designated as safety issue: No ]
Incidence and severity of atopic disease at the age of 2 years.
Complete list of historical versions of study NCT00200954 on ClinicalTrials.gov Archive Site
Serum IgE, stool composition, cytokines produced by PBMNC's [ Time Frame: Follow-up at 3 months, 12 months and 24 months ] [ Designated as safety issue: No ]
SCORAD, lung function, serum IgE, cytokines produced by PBMNC's
Not Provided
Not Provided
 
Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics
Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics.

Administration of probiotics to pregnant women from an atopic family and subsequently to their high-risk newborns results in prevention of the incidence or in a decrease of the severity of atopic disease during infancy.

Background. Atopic diseases are increasing in countries with a Western lifestyle. The hygiene hypothesis states that the increase in atopic disease could be due to reduced exposure to microbial antigens in early in life. In search of new preventive therapies for atopic disease, exposure of pregnant women with previous or recent atopic disease, and their offspring to probiotics has been suggested. Probiotics are mono or mixed cultures of microbes which, when applied to animal or man, can beneficially affect the host, among others by inducing an immune response. Probiotics are generally accepted to be safe in children. Probiotics have shown to be effective in primary prevention of atopic disease in high-risk neonates in one study so far. However, it is still unclear by what mechanism probiotics work and which is the most immunopotent (combinations of) probiotic(s). It is likely that antigen-presenting cells (APC's) are involved, since these cells are important in the first line of defence in the gastrointestinal tract. It can be imagined that the immune response is the result of the interplay between probiotics and APC's. In particular, the match between pathogen-associated molecular patterns (PAMP's) on probiotics and their counterparts on APC's, the pathogen-recognition-receptors (PRR's) (like for instance Toll-like receptors) is decisive in this aspect.

Hypothesis. Administration of probiotics to pregnant women and their offspring may reduce the development of sensitization as well as the onset of atopic disease in their offspring.

Aim. To study the effect of probiotics on sensitisation and the prevalence of atopic disease, the severity of atopic disease, the intestinal flora and immune parameters in high-risk newborns.

Methods. To study this hypothesis, a randomised, double-blind placebo-controlled trial will be carried out by administration of probiotics to pregnant women with previous or recent atopic disease as well as to their offspring. Primary outcome parameters are firstly the prevalence and severity of sensitization and atopic disease in the offspring during a follow-up of two years. Secondary outcome parameters are the change in stool composition during treatment with probiotics and in-vitro production of cytokines by PBMCs collected at 3 months, 1 year and 2 years of age.

Expected results. Perinatal administration of probiotics to pregnant women and their offspring may hamper the development of sensitization and atopic disease in their offspring. This may be due to modulation of the intestinal microbiota composition, and modulation of the developing immune system

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Food Allergy
  • Atopic Dermatitis
  • Asthma
  • Rhinitis
  • Dietary Supplement: Probiotic bacteria
    3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
  • Dietary Supplement: Placebo
    The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
  • Placebo Comparator: placebo
    placebo group
    Intervention: Dietary Supplement: Placebo
  • Active Comparator: 2
    Probiotic bacteria group
    Intervention: Dietary Supplement: Probiotic bacteria
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
157
August 2008
December 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pregnant mothers were included if either they themselves or their husband plus one sibling suffered from present or past atopic disease

Exclusion Criteria:

  • Maternal use of immunomodulatory drugs during pregnancy, the use of probiotics prior to the start of the study.
  • Children were excluded from the study if their mother received antibiotic treatment during the last two weeks of pregnancy
  • When the child was born preterm, i.e. before 37 weeks of gestation
  • If the children received antibiotic treatment in the first two weeks of life
  • If ingestion of the study product was difficult due to vomiting or feeding problems in general for longer than 3 weeks from birth
  • If the children had other major medical problems
Both
20 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00200954
PANDA
Not Provided
M.O. Hoekstra, M.D., PhD., University Medical Centre Utrecht, Wilhelmina Childrens' Hospital, The Netherlands
The Netherlands Asthma Foundation
UMC Utrecht
Principal Investigator: Maarten O Hoekstra, MD PhD Wilhelmina Children's Hospital Utrecht (UMCU)
The Netherlands Asthma Foundation
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP